报告时间：2016年1月27日（星期三）上午9：00，

　　报告地点：生物楼406会议室

　　报告人：Shuncheng Li 教授（加拿大西安大略大学）

　　报告人简介：

　　I. EDUCATION & TRAINING

　　1995-2000 Postdoctoral Fellow. Lunenfeld-Tanebaum Research Institute, Mount Sinai Hospital,

　　Toronto. Supervisor: Dr. Tony Pawson.

　　1995 Ph.D, Univ. of Toronto, Department of Biochemistry. Supervisor: Dr. Charles Deber

　　1988 MSc, Shanghai Inst. of Biochemistry & Cell Biology, Chinese Academy of Science.

　　1985 BSc, Department of Chemistry, Beijing University, Beijing.

　　II. EMPLOYMENT, PROFESSIONAL & SCHOLARLY ACTIVITIES

　　Academic Positions

　　2011-present Professor (with tenure), Department of Biochemistry and Department of Oncology, University of Western Ontario (UWO)

　　2005-2010 Associate Professor (with tenure), Department of Biochemistry, UWO.

　　2000-2005 Assistant Professor, Department of Biochemistry, Western University

　　2000-present Senior Scientist, Child Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada

　　Awards, Honors and Fellowships

　　2015 Research Excellence Award, Department of Oncology, UWO

　　2013 Top 10 Research Stories of 2013, Canadian Cancer Society Research Institute

　　2011-2016 Canada Research Chair in Functional Genomics and Cellular Proteomics (renewal)

　　2006-2011 Canada Research Chair in Functional Genomics and Cellular Proteomics (Tier II)

　　2004 Boehringer Ingelheim Young Investigator Award for the Biological Sciences

　　2004 Dean’s Award of Excellence, Schulich School of Medicine & Dentistry, UWO

　　2001 Premier’s Research Excellence Award (PREA, Government of Ontario)

　　2001 Harold E Johns Award. National Cancer Institute of Canada (NCIC).

　　2001-2007 Research Scientist Award. NCIC

　　1999-2000 Centennial Fellowship, Medical Research Council of Canada (MRC).

　　1995-1998 Fellowship, Medical Research Council of Canada.

　　1995-1998 Fellowship, National Cancer Institute of Canada (NCIC) (declined).

　　1994 RESTRACOM Award for Scientific Merit, The Hospital for Sick Children, Toronto.           

　　Supervisory Experience (summary)

　　Postdoctoral Fellows: 28;

　　Graduate Students: 12;

　　Undergraduate Students: 20;

　　Grant and Award Panels

　　2005 Operating Grants Review Panel Member for CIHR (BMA)

　　2006-2007 Operating Grants Review Panel Member for NCIC (panel F)

　　2005-2006 Review Panel member for CIHR RFA projects

　　2005-2007 Scientific Director, The Foundation for Gene and Cell Therapy, London, Ontario

　　2007-2008 Grant Reviewer for National Science Foundation, USA.

　　2009 Fellowship and scholarship Review Panel Member for Canadian Cancer Society

　　2009 Grant Reviewer for Fondazione Telethon, Italy

　　2009, 2010 Grant Reviewer for Biomedical Research Council, Singapore

　　2012 Grant Reviewer, Hongkong University of Science and Technology

　　2013 Panel Member, Canadian Cancer Society Innovation Grant

　　2014 Ad Hoc Grant Reviewer, NSERC

　　2015 Panel Member, Prostate Cancer Canada

　　2015 Panel Member, Canadian Cancer Society Innovation Grant

　　报告摘要：

　　Although tremendous advances have been made in the diagnosis and treatment of some forms of cancer following the decoding of the human genome, the initial euphoric predictions that novel disease biomarkers and new drugs would emerge in abundance from large-scale genomic analysis have not yet been realized. This reveals an urgent need for new and innovative strategies for research and drug discovery. In collaboration with the Zou group at Dalian Institute of Chemical Physics, we have developed an innovative technological platform to systematically characterize the cancer phosphoproteome- the full spectrum of proteins that are phosphorylated- with the ultimate goal to identify biomarker candidates for accurate diagnosis and prognosis of cancer. We have discovered a “protein magnet” known as phosphotyrosine- superbinder that binds to proteins phosphorylated on tyrosine, a relatively scarce protein modification associated with cancer initiation, progression and adaptation to therapies. Combining the superbinder with advanced mass spectrometry, we were able to identify protein phosphorylation in a systematic and quantitative manner. Because the superbinder is capable of capturing thousands of phosphoproteins in cancer cells or tissues, the superbinder-based phosphoproteomic strategy may be used to “fingerprint” individual cancers according to the corresponding patterns of protein phosphorylation. This systematic information on protein phosphorylation gleaned from clinical tumour sample analysis may then be used to stratify cancer patients based on drug sensitivity and guide the selection of treatment options.

　　联系人：1809组 王璐（9620）